Exelixis (EXEL) Stock

Exelixis (EXEL) has the right mix of factors that could lead to a strong earnings report in the near future. Be ready for the important expectations.

EXEL's stock dropped by 5% after Oppenheimer changed its rating from Outperform to Perform. This downgrade was due to worries about how well the new drug candidate zanzalintinib will compare to cabozantinib, especially after the STELLAR-001 study abstract was released.

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) has shared results from an expanded group in the phase 1b/2 STELLAR-001 trial, which looked at zanzalintinib alone or with atezolizumab (Tecentriq®) for patients with previously treated metastatic colorectal cancer (CRC). These results will be presented during Poster Session C: Cancers of the Colon, Rectum and Anus, at 7:00 a.m. PT on January 25 at the American Society of Clinical Oncology 2025 Gastrointestinal Cancer conference.

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) has shared findings from a subgroup analysis of the phase 3 CABINET study focused on patients with extra-pancreatic neuroendocrine tumors (epNET) in the gastrointestinal (GI) tract. The analysis indicated that cabozantinib led to better progression-free survival (PFS) compared to a placebo in patients with advanced GI neuroendocrine tumors (NET), which is part of the epNET group. These results are significant.

Shares of the cancer treatment company Exelixis, Inc. (EXEL) are increasing due to higher revenue and advancements in their product development.

The approval of new drugs and advancements in research are expected to keep the Zacks Biomedical and Genetics industry moving forward, even with the unpredictable economic situation. Companies like INCY, BMRN, EXEL, HALO, and BPMC have a strong range of products and promising research, which gives them an advantage in this unstable market.

Exelixis (EXEL) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.

The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons to make the most of this tool.

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) has shared its early financial results for the fiscal year 2024, along with its financial outlook for 2025 and a business update. The company expects 2025 to focus on clinical and regulatory activities, as well as ongoing growth for its cabozantinib products, and plans to release several data updates for zanzalintinib and its range of small molecules and biotherapeutics.